Related Experiment Video
Updated: Oct 3, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
The prognostic impact of Claudin 6 in papillary renal cell carcinoma
Marie Mikuteit1, Stefanie Zschäbitz2, Christine Stöhr3
1Department of Rheumatology and Immunology, Hannover Medical School, 30625 Hannover, Germany; Department of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany; Institute of Pathology, University Hospital Erlangen-Nuernberg, Friedrich Alexander University (FAU), 91054 Erlangen, Germany; Department of Urology, University Hospital Münster, 48149 Münster, Germany; Department of Urology, University Hospital Göttingen, 37075 Göttingen, Germany; Department of Pathology, University Hospital Göttingen, 37075 Göttingen, Germany; Department of Urology and Pediatric Urology, University Hospital Saarland (UKS), 66421 Homburg, Germany; Department of Urology, University Hospital Marburg, 35037 Marburg, Germany; Department of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany; Institute of Pathology, University Hospital Mainz, 55131 Mainz, Germany; Department of Urology and Pediatric Urology, University Hospital Erlangen, 91058 Erlangen, Germany; Department of Urology, Marien-Hospital Herne, Ruhr University Bochum, 44625 Herne, Germany; Department of Urology, University Hospital Mainz, 55131 Mainz, Germany; Department of Urology, University Hospital Frankfurt, 60590 Frankfurt/Main, Germany; Department of Urology, University Hospital Regensburg, 93053 Regensburg, Germany; Department for Rheumatology and Immunology, Hannover Medical School, 30625 Hannover, Germany.
Background:
Claudins are promising biomarkers for diagnosis and prognosis or targets for treatment. They play a major role in signal transduction and are important in nearly all aspects of tumorigenesis. Claudin 6 is a member of the claudin family and is part of the tight junction molecule. It is reactivated in several cancer types and serves as prognostic marker in, for example, gastric, breast or non small cell lung cancer. The prognostic role of Claudin 6 in renal cell carcinoma (RCC), especially in papillary RCC (pRCC), is still unclear.
Patients And Methods:
The patients' sample collection was a joint collaboration of the PANZAR consortium. Patients' medical history and tumor specimens were collected from n = 240 and n = 128 patients with type 1 and 2 pRCC, respectively. Expression of Claudin 6 was determined by immunohistochemistry.
Results:
In total, Claudin 6 staining was positive in 55 of 240 type 1 and 30 of 128 type 2 pRCC cases. Kaplan-Meier analysis disclosed an overall survival of 84% for Claudin 6- compared to 78% for Claudin 6 + in pRCC type 1 tumors (p = 0.449, log-rank) and 68% for Claudin 6- compared to 65.4% for Claudin 6 + in pRCC type 2 tumors (p = 0.364, log-rank).
Conclusion:
In this study, claudin 6 expression showed no significant association regarding overall survival (OS) and therefore did not qualify as a prognostic marker in pRCC. Future studies will have to determine, whether Claudin 6 plays a prognostic role in other RCC entities. In addition, the function of Claudin 6 as a predictive marker for therapeutic approaches has to be evaluated in future studies.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...